Search Results - "Hutter, Grit"

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date by Seiler, Till, Hutter, Grit, Dreyling, Martin

“…The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological…”
Get full text

3'UTR mediated regulation of the cyclin D1 proto-oncogene by Deshpande, Anagha, Pastore, Alessandro, Deshpande, Aniruddha. J., Zimmermann, Yvonne, Hutter, Grit, Weinkauf, Marc, Buske, Christian, Hiddemann, Wolfgang, Dreyling, Martin

“…In mantle cell lymphoma (MCL), over-expression of cyclin D1 is the hallmark of malignant transformation and results from it's juxtaposition to the…”
Get full text

Transient antagonism of anti‐ CD 20 monoclonal antibodies and PI 3K inhibitor idelalisib in DLBCL cell lines by Zoellner, Anna‐Katharina, Peter, Nico, Zimmermann, Yvonne, Hutter, Grit, Hiddemann, Wolfgang, Dreyling, Martin

Get full text

Differential regulation patterns of the anti‐CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma by Heinrich, Daniel A., Weinkauf, Marc, Hutter, Grit, Zimmermann, Yvonne, Jurinovic, Vindi, Hiddemann, Wolfgang, Dreyling, Martin

Get full text

Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway by Zoellner, Anna-Katharina, Bayerl, Stephan, Hutter, Grit, Zimmermann, Yvonne, Hiddemann, Wolfgang, Dreyling, Martin

“…Lately, mTOR inhibitors have gained clinical relevance in malignant lymphoma. Still, rapamycin derivatives may activate a pro-survival feedback loop through…”
Get full text

Combination of PI3K and PDPK1 Inhibitors Is Highly Effective in Mantle Cell Lymphoma by Hutter, Grit, Zimmermann, Yvonne, Zoellner, Anna-Katharina, Irrgang, Philip, Weigert, Oliver, Hiddemann, Wolfgang, Dreyling, Martin

“…Introduction: Mantle cell lymphoma (MCL), is a distinct lymphoma subtype with an aggressive clinical course and a median survival of 3-5 years. New emerging…”
Get full text

The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive with Ibrutinib by Fischer, Luca, Schnaiter, Andrea, Freysoldt, Bianca, Irger, Markus, Zimmermann, Yvonne, Hutter, Grit, Hiddemann, Wolfgang, Dreyling, Martin H.

“…Introduction: Mantle cell lymphoma (MCL) is characterized by t(11;14) resulting in a constitutive cyclin D1 overexpression. The cyclin D1-CDK4/6 complex…”
Get full text

Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL) by Freysoldt, Bianca, Schnaiter, Andrea, Fischer, Luca, O'Neill, Michael, Zimmermann, Yvonne, Hutter, Grit, Hiddemann, Wolfgang, Dreyling, Martin H.

“…Introduction: Mantle cell lymphoma (MCL) comprises about 6% of all non-Hodgkin's lymphoma with a median survival of 3-5 years. Constitutional activation of the…”
Get full text

Transient antagonism of anti‐CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines by Zoellner, Anna‐Katharina, Peter, Nico, Zimmermann, Yvonne, Hutter, Grit, Hiddemann, Wolfgang, Dreyling, Martin

“…Introduction PI3K inhibitors are evaluated for relapsed and refractory Diffuse large B‐cell lymphoma (DLBCL) patients. Objective As rituximab has shown to…”
Get full text

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma by Hutter, Grit, Rieken, Malte, Pastore, Alessandro, Weigert, Oliver, Zimmermann, Yvonne, Weinkauf, Marc, Hiddemann, Wolfgang, Dreyling, Martin

“…Single-agent bortezomib, a potent, selective, and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory…”
Get full text

Rituximab But Not GA101 Is Partially Antagonistic With Inhibitors Of The B-Cell Receptor Pathway In Diffuse Large B-Cell Lymphoma by Zoellner, Anna-Katharina, Peter, Nico, Hutter, Grit, Zimmermann, Yvonne, Hiddemann, Wolfgang, Dreyling, Martin

“…Anthracyclin-containing immuno-chemotherapy represents the current standard approach in diffuse large cell B cell lymphoma (DLBCL). However, especially in ABC…”
Get full text

High Efficiency Of the PDPK1-Inhibitor, BX912, In MCL by Hutter, Grit, Zimmermann, Yvonne, Giller, Vladimir, Zoellner, Anna-Katharina, Weigert, Oliver, Hiddemann, Wolfgang, Dreyling, Martin

“…Mantle cell lymphoma (MCL) is an aggressive lymphoid malignancy with a median survival of 3-5 years. New strategies including proteasome inhibitors, immune…”
Get full text

Temsirolimus acts as additive with bendamustine in aggressive lymphoma by Zoellner, Anna-Katharina, Weiglein, Tobias, Hutter, Grit, Zimmermann, Yvonne, Cieplik, Hans Christian, Hess, G., Dreyling, Martin

“…The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway. It plays a pivotal…”
Get full text

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network by Dreyling, Martin, Kluin-Nelemans, Hanneke C., Beà, Sílvia, Klapper, Wolfram, Vogt, Niclas, Delfau-Larue, Marie-Helene, Hutter, Grit, Cheah, Chan, Chiappella, Annalisa, Cortelazzo, Sergio, Pott, Christiane, Hess, Georg, Visco, Carlo, Vitolo, Umberto, Klener, Pavel, Aurer, Igor, Unterhalt, Michael, Ribrag, Vincent, Hoster, Eva, Hermine, Olivier

“…Abstract Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in…”
Get full text

Differential Regulation Patterns of Anti-CD20 Antibodies GA101 and Rituximab in Mantle Cell Lymphoma by Heinrich, Daniel, Weinkauf, Marc, Hutter, Grit, Decheva, Kristina, Zimmermann, Yvonne, Hiddemann, Wolfgang, Dreyling, Martin H.

“…Abstract 1839 Mantle cell lymphoma (MCL) is a distinct lymphoma subtype characterized by a poor long-term prognosis. Rituximab, a chimeric type I anti-CD20…”
Get full text

Proteasome Inhibition Leads to Dephosphorylation and Downregulation of Protein Expression of Members of the Akt/mTOR Pathway In MCL by Hutter, Grit, Zimmermann, Yvonne, Rieken, Malte, Hartmann, Elena, Hiddemann, Wolfgang, Rosenwald, Andreas, Dreyling, Martin H.

“…Abstract 4449 Mantle cell Lymphoma (MCL) is a distinct B-cell subtype characterized by the chromosomal translocation t(11;14)(q13;q32), an especially poor…”
Get full text

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma by Weinkauf, Marc, Zimmermann, Yvonne, Hartmann, Elena, Rosenwald, Andreas, Rieken, Malte, Pastore, Alessandro, Hutter, Grit, Hiddemann, Wolfgang, Dreyling, Martin

“…Although gene expression following bortezomib treatment has been previously explored, direct effects of bortezomib-induced proteasome inhibition on protein…”
Get full text

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network by Dreyling, Martin, Kluin-Nelemans, Hanneke C., Beà, Sílvia, Hartmann, Elena, Salaverria, Itziar, Hutter, Grit, Perez-Galan, Patricia, Roue, Gael, Pott, Christiane, Gouill, Steven Le, Cortelazzo, Sergio, Rule, Simon, Hess, Georg, Zaja, Francesco, Vitolo, Umberto, Szymczyk, Michal, Walewski, Jan, Ribrag, Vincent, Unterhalt, Michael, Hermine, Olivier, Hoster, Eva

“…Abstract Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in…”
Get full text

Enzastaurin Treatment Affects Multiple Regulatory Pathways at Transcriptome and Cellular Proteome Level of Mantle Cell Lymphoma by Weinkauf, Marc, Hutter, Grit, Zimmermann, Yvonne, Rieken, Malte, Pastore, Alessandro, Hartmann, Elena, Rosenwald, Andreas, Hiddemann, Wolfgang, Dreyling, Martin H.

“…Abstract 2893 The protein kinase C beta inhibitor enzastaurin is one of the promising molecular targeted approaches currently investigated in mantle cell…”
Get full text

Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma by Weinkauf, Marc, Hutter, Grit, Zimmermann, Yvonne, Hartmann, Elena, Rosenwald, Andreas, Dreyling, Martin

“…Despite recent advances in treatment, mantle cell lymphoma (MCL) still represents a disease with dismal prognosis due to its progressive clinical course, high…”
Get full text